P0754 - In-Hospital Outcomes of Opioid-Dependent Inflammatory Bowel Disease in Cannabis vs Non-Cannabis Users: A Nationwide Propensity Matched Analysis in the United States

Rewanth Katamreddy, MD¹, Samuel Edusa, MD², Yamini Katamreddy, MD³, Ummul Asfeen, DO⁴, Jayasree Ravilla, MD⁵, Ali Tariq Alvi, MD⁶, Charu Agarwal, MBBS⁷, Birimroz Singh Sibia, MBBS⁸, Aleen Rahman, MBBS⁹, Fnu Vikash, MD¹⁰, Rupak Desai, MBBS^11
1Saint Michael’s Medical Center, Newark, NJ; ²Piedmont Athens Regional, Athens, GA; ³West Anaheim Medical Center, Anaheim, CA; ⁴NYMC-Saint Michaels Medical Center, Newark, NJ; ⁵Monmouth Medical Center/RWJBH, Long Branch, NJ; ⁶HCA Florida Westside Hospital, Plantation, FL; ⁷Sri Sidhartha Medical College, Aurora, IL; ⁸KMC-Manipal, Manipal, Karnataka, India; ⁹Fatima Jinnah Medical University, San Jose, CA; ¹⁰Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY; ¹¹Outcomes Research, Atlanta, GA

Introduction: According to the literature, Inflammatory Bowel Disease (IBD) patients with opioid dependency have a threefold higher mortality risk than non-users. Some studies suggest the role of cannabis usage in IBD due to its anti-inflammatory properties. However, no literature indicates the impact of cannabis usage on opioid-dependent IBD. Using a national propensity-matched sample, we assessed inpatient hospital outcomes of opioid-dependent IBD patients with Cannabis Use Disorder (CUD) versus non-CUD.

Methods: The Nationwide Inpatient Sample database (2019) was queried to identify opioid-dependent IBD in CUD versus non-CUD cohorts. A Pearson Chi-square test and Mann-Whitney U tests were used to compare categorical and continuous variables between propensity-matched cohorts. In-hospital complications were the primary outcome; Length-Of-Stay and hospital expenses were secondary.

Results: Of all opioid-dependent IBD hospitalizations, age and sex-matched CUD and non-CUD cohorts were studied. Both groups had 995 patients and a median age of 37 and shared similar sociodemographic characteristics. Comorbidities such as alcohol use disorder (18.1% vs. 6.0%; p< 0.001), complicated hypertension (8.5% vs. 4.5%; p< 0.001), tobacco use disorder (59.8% vs. 44.2%; p< 0.001), and chronic pulmonary disease (25.6% vs. 20.6%; p=0.008) were more common in the CUD cohort. The CUD cohort had higher odds of AKI (OR:1.94; 95CI:1.02-3.68; p=0.043), which was statistically significant, unlike MACCE (OR:1.28; 95CI:0.26-6.21; p=0.761) and sepsis (OR:3.35; 95CI:0.56-20.23; p=0.186). Although not statistically significant, the CUD cohort had lower odds of intestinal obstruction and non-routine discharge compared to routine discharge. The CUD cohort also had a more extended hospital stay (5 vs. 4 days) and higher hospital charges ($31847 vs. $31190; p=0.066).

Discussion: Our study shows that the CUD cohort had higher odds of AKI versus the non-CUD cohort in opioid-dependent IBD. Given the increased frequency of polysubstance use in the United States, additional prospective studies on the dosage, mode, and duration of recreational or medicinal cannabis use in opioid-dependent IBD patients are necessary.



Disclosures:


Rewanth Katamreddy, MD¹, Samuel Edusa, MD², Yamini Katamreddy, MD³, Ummul Asfeen, DO⁴, Jayasree Ravilla, MD⁵, Ali Tariq Alvi, MD⁶, Charu Agarwal, MBBS⁷, Birimroz Singh Sibia, MBBS⁸, Aleen Rahman, MBBS⁹, Fnu Vikash, MD¹⁰, Rupak Desai, MBBS¹¹. P0754 - In-Hospital Outcomes of Opioid-Dependent Inflammatory Bowel Disease in Cannabis vs Non-Cannabis Users: A Nationwide Propensity Matched Analysis in the United States, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.